The Geely E2 (EX2) electric car has reached one million units sold globally within two years of its launch in October 2024, marking rapid market acceptance. It became the world's best-selling car in A&B segments in 2025 and topped sales charts in countries like Australia, South Africa, Jordan, and Mexico. Known for its safety, smart features, and urban-friendly design, the E2 (EX2) is now available in over 30 markets worldwide. This milestone underscores Geely Auto's strength in delivering competitive electric vehicles and sets the stage for further global expansion.
The Geely E2 (EX2) electric car's milestone of one million global sales in two years provides context for consumer cyclical market activity. For readers following this sector, here is Pluang's market snapshot as of Nov 03, 2026 05:41 WIB: out of 134 priced US stocks, 96 rose and 37 fell. Notable movers include PRTS at USD 6.95 with a 19.37% decline, BIRD at USD 1.64 with a 15.90% drop and a 77% buy order activity, and RENT at USD 2.17 with a 10.14% decrease and 100% sell order activity.
AI data centers are expanding beyond traditional land-based locations due to increasing power and space constraints. Companies like Aikido Technologies are exploring floating data centers powered by offshore wind, while Elon Musk's SpaceX plans to de...
Global Indemnity Group will postpone its third quarter 2026 earnings call originally scheduled for November 4 to January, when new CEO Jessica Buss will present her vision and priorities for the company. The company will still release its Q3 results ...
Lorraine Ben, former CEO of Lockheed Martin Canada, has joined Syntax Defence to provide expert counsel amid Canada's commitment to invest over half a trillion dollars in defence over the next decade. This includes $180 billion in procurement opportu...
Zentalis Pharmaceuticals awarded 136,000 non-qualified stock options to four newly hired employees as an inducement to join the company, under Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $1.85, matching the stock's closing p...
Dianthus Therapeutics, a clinical-stage biotech company, granted stock options to three new non-executive employees as inducements for joining the company. The options cover 26,000 shares at an exercise price of $82.25, vesting over four years. This ...
